[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CL2020000281A1 - Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39 y métodos de uso de anticuerpos anti-cd39 - Google Patents

Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39 y métodos de uso de anticuerpos anti-cd39

Info

Publication number
CL2020000281A1
CL2020000281A1 CL2020000281A CL2020000281A CL2020000281A1 CL 2020000281 A1 CL2020000281 A1 CL 2020000281A1 CL 2020000281 A CL2020000281 A CL 2020000281A CL 2020000281 A CL2020000281 A CL 2020000281A CL 2020000281 A1 CL2020000281 A1 CL 2020000281A1
Authority
CL
Chile
Prior art keywords
antibodies
compositions
methods
Prior art date
Application number
CL2020000281A
Other languages
English (en)
Inventor
Courtney Beers
Vanessa Soros
Maria Kovalenko
John Corbin
Paul Fredrick Widboom
Joseph Robert Warfield
Original Assignee
Tizona Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tizona Therapeutics filed Critical Tizona Therapeutics
Publication of CL2020000281A1 publication Critical patent/CL2020000281A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
CL2020000281A 2017-07-31 2020-01-31 Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39 y métodos de uso de anticuerpos anti-cd39 CL2020000281A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762539527P 2017-07-31 2017-07-31

Publications (1)

Publication Number Publication Date
CL2020000281A1 true CL2020000281A1 (es) 2020-12-18

Family

ID=65233024

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020000281A CL2020000281A1 (es) 2017-07-31 2020-01-31 Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39 y métodos de uso de anticuerpos anti-cd39

Country Status (22)

Country Link
US (5) US11345757B2 (es)
EP (1) EP3661966A4 (es)
JP (3) JP7113071B2 (es)
KR (2) KR102718932B1 (es)
CN (1) CN111448211B (es)
AR (1) AR112639A1 (es)
AU (1) AU2018312251A1 (es)
BR (1) BR112020002012A8 (es)
CA (1) CA3071540A1 (es)
CL (1) CL2020000281A1 (es)
CO (1) CO2020001983A2 (es)
CR (1) CR20200101A (es)
DO (1) DOP2020000021A (es)
IL (1) IL272367A (es)
MX (1) MX2020001270A (es)
MY (1) MY202018A (es)
PE (1) PE20200617A1 (es)
PH (1) PH12020500240A1 (es)
SG (2) SG10202111869SA (es)
TW (2) TW202344516A (es)
WO (1) WO2019027935A1 (es)
ZA (1) ZA202000608B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2848323T3 (es) 2008-01-31 2021-08-06 Inst Nat Sante Rech Med Anticuerpos contra CD39 humano y uso de los mismos para inhibir la actividad de las células T reguladoras
KR102584011B1 (ko) 2017-03-16 2023-09-27 이나뜨 파르마 에스.에이. 암 치료를 위한 조성물 및 방법
EP3661966A4 (en) 2017-07-31 2021-07-21 Tizona Therapeutics ANTI-CD39 ANTIBODIES, COMPOSITIONS INCLUDING ANTI-CD39 ANTIBODIES AND METHODS OF USE OF ANTI-CD39 ANTIBODIES
CN113754768B (zh) * 2018-03-14 2023-01-06 表面肿瘤学公司 结合cd39的抗体及其用途
JP7368453B2 (ja) 2018-05-03 2023-10-24 シャンハイ エピムアブ バイオセラピューティクス カンパニー リミテッド Ｐｄ－１およびｌａｇ－３に対する高親和性抗体ならびにそれらから作製された二重特異性結合タンパク質
EA202092518A1 (ru) 2018-06-18 2021-08-23 Иннейт Фарма Композиции и способы лечения рака
EP3818083A2 (en) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
JP2022544549A (ja) * 2019-08-12 2022-10-19 ピュリノミア バイオテック， インコーポレイテッド Ｃｄ３９発現細胞のａｄｃｃ標的化を介してｔ細胞媒介性免疫応答を促進及び増強するための方法及び組成物
BR112022002351A2 (pt) * 2019-09-16 2022-07-19 Surface Oncology Inc Composições e métodos de anticorpo anti-cd39
CN110407941B (zh) * 2019-09-25 2020-01-14 上海岸迈生物科技有限公司 Cd39的高亲和力抗体及其用途
CN114651013A (zh) * 2019-11-05 2022-06-21 北京加科思新药研发有限公司 对cd39具有特异性的结合分子及其用途
AU2021245936A1 (en) * 2020-04-03 2022-11-03 Trishula Therapeutics, Inc. Combination therapy involving anti-CD39 antibodies and adoptive cell therapy
JPWO2021260966A1 (es) * 2020-06-25 2021-12-30
JP2023548045A (ja) 2020-10-23 2023-11-15 アッシャー バイオセラピューティクス， インコーポレイテッド 免疫細胞機能をモジュレートするためのｃｄ８抗原結合分子を有する融合物
CN115052894A (zh) * 2020-11-27 2022-09-13 科望(苏州)生物医药科技有限公司 靶向cd39和tgfbeta的新型缀合物分子
CA3209479A1 (en) 2021-02-03 2022-08-11 Mozart Therapeutics, Inc. Binding agents and methods of using the same
EP4340866A1 (en) 2021-05-19 2024-03-27 Asher Biotherapeutics, Inc. Il-21 polypeptides and targeted constructs
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
WO2023138643A1 (zh) * 2022-01-24 2023-07-27 上海华奥泰生物药业股份有限公司 Cd39抗原结合蛋白及其应用
KR20240156633A (ko) 2022-03-03 2024-10-30 아르커스 바이오사이언시즈 인코포레이티드 항-cd39 항체 및 이의 용도
WO2023164872A1 (en) * 2022-03-03 2023-09-07 Arcus Biosciences, Inc. Anti-cd39 antibodies and use thereof
WO2023168113A1 (en) * 2022-03-04 2023-09-07 Trishula Therapeutics, Inc. Combinations with an anti human cd39 antibody, an anti human pd-1 antibody, and chemotherapy in gastric cancer
WO2023182530A1 (ja) * 2022-03-25 2023-09-28 ブライトパス・バイオ株式会社 抗ｃｄ３９抗体
WO2023201267A1 (en) 2022-04-13 2023-10-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
WO2024030956A2 (en) 2022-08-03 2024-02-08 Mozart Therapeutics, Inc. Cd39-specific binding agents and methods of using the same
WO2024115935A1 (en) 2022-11-29 2024-06-06 Inserm Methods for the treatment of b-cell lymphoma using cd39 inhibitors
WO2024175760A1 (en) * 2023-02-24 2024-08-29 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of endometriosis

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4485696A (en) 1995-01-18 1996-08-07 Boehringer Mannheim Gmbh Anti-cd 30 antibodies preventing proteolytic cleavage and release of membrane-bound cd 30 antigen
AU5265296A (en) 1995-04-10 1996-10-30 Universite De Sherbrooke Atp-diphosphohydrolases, process of purification thereof and process of producing thereof by recombinant technology
US6447771B1 (en) 1999-03-19 2002-09-10 Hyseq, Inc. Methods and materials relating to novel CD39-like polypeptides
IL140931A0 (en) 1998-07-16 2002-02-10 Hyseq Inc Methods and materials relating to novel cd39-like polypeptides
US6476211B1 (en) 1998-07-16 2002-11-05 Hyseq, Inc. Methods and materials relating to CD39-like polypeptides
US6387645B1 (en) 1998-07-16 2002-05-14 Hyseq, Inc. Methods and materials relating to novel CD39-like polypeptides
US6899875B1 (en) 1999-01-29 2005-05-31 Nuvelo, Inc. Methods and compositions relating to CD39-like polypeptides and nucleic acids
US6350447B1 (en) 1999-01-29 2002-02-26 Hyseq, Inc. Methods and compositions relating to CD39-like polypeptides and nucleic acids
US6780977B1 (en) 1999-01-29 2004-08-24 Nuvelo, Inc. Methods and compositions relating to CD39-like polypeptides and nucleic acids
US6335013B1 (en) 1999-03-19 2002-01-01 Hyseq, Inc. Methods and materials relating to CD39-like polypeptides
AU2002361763A1 (en) 2001-12-17 2003-06-30 Beth Israel Deaconess Medical Center Method of reducing angiogenesis
US20050037382A1 (en) 2003-04-08 2005-02-17 Robson Simon C. Methods and compositions for treating and preventing autoimmune disorders
WO2006111986A1 (en) 2005-04-19 2006-10-26 Fondazione Santa Lucia I.R.C.C.S. Method for the detection and the isolation of immunosuppressive regulatory t cells and uses thereof
US9624309B2 (en) 2007-08-15 2017-04-18 Bayer Intellectual Property Gmbh Monospecific and multispecific antibodies and method of use
AR069746A1 (es) 2007-11-30 2010-02-17 Medarex Inc Conjugados de anticuerpos anti- rg-1
ES2848323T3 (es) 2008-01-31 2021-08-06 Inst Nat Sante Rech Med Anticuerpos contra CD39 humano y uso de los mismos para inhibir la actividad de las células T reguladoras
DK2356270T3 (da) * 2008-11-07 2016-12-12 Fabrus Llc Kombinatoriske antistofbiblioteker og anvendelser deraf
US20130273062A1 (en) 2010-12-22 2013-10-17 Orega Biotech Antibodies against human cd39 and use thereof
EP2809682B1 (en) * 2012-02-03 2020-04-08 F.Hoffmann-La Roche Ag Bispecific antibody molecules with antigen-transfected t-cells and their use in medicine
AU2015241422B2 (en) * 2014-04-01 2020-12-03 Rubius Therapeutics, Inc. Methods and compositions for immunomodulation
EP3215538A4 (en) 2014-11-07 2018-07-04 Igenica Biotherapeutics, Inc. Anti-cd39 antibodies and uses thereof
ES2807182T3 (es) 2014-11-21 2021-02-22 Bristol Myers Squibb Co Anticuerpos frente a CD73 y sus usos
US20180140724A1 (en) 2015-05-27 2018-05-24 The Trustees Of Columbia University In The City Of New York Tumor Deliverable Iron and Protein Synthesis Inhibitors as a New Class of Drugs for the Diagnosis and Treatment of Cancer
SG10201912736UA (en) * 2015-10-01 2020-02-27 Potenza Therapeutics Inc Anti-tigit antigen-binding proteins and methods of use thereof
US11130817B2 (en) 2015-10-12 2021-09-28 Innate Pharma CD73 blocking agents
EP3380519A1 (en) 2015-11-23 2018-10-03 Innate Pharma Cd39 vascular isoform targeting agents
EP3429692A1 (en) 2016-03-14 2019-01-23 Innate Pharma Anti-cd39 antibodies
ES2820173T3 (es) 2016-05-06 2021-04-19 Inst Nat Sante Rech Med Composiciones farmacéuticas para el tratamiento de la leucemia mieloide aguda (LMA) quimiorresistente
WO2018065552A1 (en) 2016-10-06 2018-04-12 Innate Pharma Anti-cd39 antibodies
US10570167B2 (en) 2016-12-22 2020-02-25 Calithera Biosciences, Inc. Ectonucleotidase inhibitors and methods of use thereof
KR102584011B1 (ko) 2017-03-16 2023-09-27 이나뜨 파르마 에스.에이. 암 치료를 위한 조성물 및 방법
EP3661966A4 (en) 2017-07-31 2021-07-21 Tizona Therapeutics ANTI-CD39 ANTIBODIES, COMPOSITIONS INCLUDING ANTI-CD39 ANTIBODIES AND METHODS OF USE OF ANTI-CD39 ANTIBODIES
CA3074588A1 (en) 2017-10-06 2019-04-11 Innate Pharma Restoration of t cell activity via the cd39/cd73 axis
CA3075371A1 (en) 2017-11-15 2019-05-23 Innate Pharma Potentiating the effect of atp release
CN113754768B (zh) 2018-03-14 2023-01-06 表面肿瘤学公司 结合cd39的抗体及其用途
JP2022544549A (ja) 2019-08-12 2022-10-19 ピュリノミア バイオテック， インコーポレイテッド Ｃｄ３９発現細胞のａｄｃｃ標的化を介してｔ細胞媒介性免疫応答を促進及び増強するための方法及び組成物
AU2020286284B2 (en) 2019-08-27 2023-11-09 Elpiscience (Suzhou) Biopharma, Ltd. Novel anti-CD39 antibodies
BR112022002351A2 (pt) 2019-09-16 2022-07-19 Surface Oncology Inc Composições e métodos de anticorpo anti-cd39
CN110407941B (zh) 2019-09-25 2020-01-14 上海岸迈生物科技有限公司 Cd39的高亲和力抗体及其用途

Also Published As

Publication number Publication date
RU2020108524A (ru) 2021-09-02
IL272367A (en) 2020-03-31
MY202018A (en) 2024-03-29
PH12020500240A1 (en) 2021-01-04
JP2024079809A (ja) 2024-06-11
CR20200101A (es) 2020-04-15
US11345757B2 (en) 2022-05-31
KR20200033928A (ko) 2020-03-30
CN111448211A (zh) 2020-07-24
JP2022145720A (ja) 2022-10-04
CN111448211B (zh) 2024-06-07
JP2020530289A (ja) 2020-10-22
KR102718932B1 (ko) 2024-10-17
KR20240153413A (ko) 2024-10-22
JP7113071B2 (ja) 2022-08-04
TW202344516A (zh) 2023-11-16
AU2018312251A1 (en) 2020-02-20
AR112639A1 (es) 2019-11-20
SG10202111869SA (en) 2021-11-29
EP3661966A4 (en) 2021-07-21
SG11202000820PA (en) 2020-02-27
US20190062448A1 (en) 2019-02-28
US20210009708A1 (en) 2021-01-14
BR112020002012A8 (pt) 2022-06-28
US20210403593A1 (en) 2021-12-30
TWI798242B (zh) 2023-04-11
PE20200617A1 (es) 2020-03-11
BR112020002012A2 (pt) 2020-09-01
CO2020001983A2 (es) 2020-04-01
DOP2020000021A (es) 2020-08-16
CA3071540A1 (en) 2019-02-07
US20220340680A1 (en) 2022-10-27
US20220372163A1 (en) 2022-11-24
MX2020001270A (es) 2020-09-22
EP3661966A1 (en) 2020-06-10
WO2019027935A1 (en) 2019-02-07
TW201920277A (zh) 2019-06-01
ZA202000608B (en) 2022-07-27

Similar Documents

Publication Publication Date Title
CL2020000281A1 (es) Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39 y métodos de uso de anticuerpos anti-cd39
CL2019002503A1 (es) Compuesto de sulfamida cíclico y métodos de uso de los mismo.
KR102162129B9 (ko) 항-갈렉틴-9 항체 및 이의 용도
MA46525A (fr) Anticorps anti-lag-3 et compositions
KR20180084817A (ko) 항-siglec-9 항체 및 이의 이용 방법
CL2018000813A1 (es) Conjugados de anticuerpo-fármaco de pirrolobenzodiazepina y métodos de uso.
CR20180013A (es) Anticuerpos anti-tau y métodos de uso.
MA44659A (fr) Anticorps anti-tim-3 et compositions
CL2018000479A1 (es) Linfoopeitina strimal tomica (tslp) - anticuerpos de union y metodos de uso de los anticuerpos
CL2017000590A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
CL2018000833A1 (es) Anticuerpos agonistas que se unen específicamente a cd40 humana y métodos de uso.
CL2016001102A1 (es) Anticuerpos anti-claudina novedosos y métodos de uso.
BR112017025828A2 (pt) dispositivo de nó hospedeiro e métodos de uso com o mesmo.
CL2016002364A1 (es) Indazol-3-carboxamidas 5-sustituidas y preparación y uso de las mismas
CL2018001139A1 (es) Anticuerpos anti-htra1 y métodos de uso de los mismos.
BR112015032224A2 (pt) anticorpos anti-fcrh5
DK3368572T3 (da) Anti-pd-1-antistoffer og -sammensætninger
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
BR112017024899A2 (pt) proteínas de ligação trispecíficas e métodos de uso.
BR112019012343A2 (pt) anticorpos il-11ra
CL2016001432A1 (es) Nuevos anticuerpos anti-dpep3 y métodos de uso
CR20170230A (es) Anticuerpos anti-cd79b y métodos de uso
BR112016022658A2 (pt) anticorpos anti-ox40 e métodos de uso
BR112017008666A2 (pt) anticorpos anti-fgfr2/3 e métodos de uso dos mesmos
CR20160362A (es) Anticuerpos anti-jagged1 y metodos de uso